Recorded: 08 May 2008
Another interesting thing which we did which was, quite interesting, was we looked at pharmacogenomics markers. So in the literature there’s a lot of data out about genetic profiles related to drugs. So what drugs you should do, and a lot has to do with metabolizing statuses. So we checked his metabolizing statuses. So we sort of came up with a profile for him: if he ever has a heart attack, what would be the dosage be for his warfarin. We did analysis on all the metabolizing genes. So it turns out for a very large group of drugs he’s a fast metabolizer. So that means is that he should take actually a higher dosage. So it was quite interesting to see this on a very complete way. And I think it’s also very interesting to see for doctors, now we have a real data to get an idea. Now obviously, immediately he doesn’t need it. Only if he gets treated, only if he goes into the hospital. So, it was very interesting.
Martin Reese is the Co-founder, Chief Executive Officer, and Chairman of the Board of Omicia.
Dr. Martin Reese is an internationally recognized expert in medical informatics and bioinformatics with a track record of bringing strong, grounded scientific knowledge to the corporate sector. Prior to founding Omicia, Dr. Reese served as Vice President of Discovery Informatics for ValiGen. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project. This project provided the essential proof-of-concept platform for Celera's famous shotgun sequencing technology, which is now internationally recognized - as driving a new standard of excellence in sequencing. It was while at the Lawrence Berkeley National Laboratories that Dr. Reese developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of California, Berkeley and the University of Hohenheim, Germany.